UE – co-financed projects implemented

Preclinical and clinical development of a first-in-class, innovative, bispecific immunotherapeutic agent as a drug candidate in cancer immunotherapy 

Development of an innovative, class-leading, low-molecular, double-oriented therapeutic agent having immunomodulating and cytotoxic effects as a drug candidate for the treatment of leukaemia and solid tumours

UBA – Preclinical and clinical development of the ubiquitin-proteasome system inhibitor as an innovative drug used in cancer treatment.

AMDBP – Development of a production platform for biosimilars based on CHO cells and an innovative expression system and preclinical and clinical development of a biosimilar drug based on a Fab fragment.

GATE – Preclinical and clinical development of an innovative antagonist of GPR40 receptor in type 2 diabetes treatment

FAIND – A new diabetes treatment using an innovative FGF1 protein analogue.

A new form of S-ketamine in treatment of depression

“Fostering Celon Pharma S.A. research infrastructure by creating a Research&Development Centre (RDC)”